Adaptimmune Alternatives & Competitors

12 companies similar to Adaptimmune — Designing and delivering cell therapies to transform the lives of people with ca...

Imvax, Inc.

Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-deriv...

24 Unknown $253.70M

Philadelphia, United Stat...

Biotechnology Health and Wellness +1

Avenzo Therapeutics

Developing the next generation of oncology therapies for patients

61 Unknown $661.00M

San Diego, United States

Biotechnology Health Care +1

Adendra Therapeutics

Translating dendritic cell biology into new therapies for cancer and autoimmunity.

3 Series A $53.00M

London, United Kingdom

Biopharma Biotechnology +1

Enara Bio

Advancing cancer immunotherapy by targeting the unconventional

66 Series B $50.00M

Oxford, United Kingdom

Biotechnology Health Care +1

Track all Adaptimmune competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Flare Therapeutics

Trailblazing the path to drugging transcription factors to discover precision medicines fo...

62 Series B $205.00M

Cambridge, United States

Biopharma Biotechnology +2

NextRNA Therapeutics

Leading The Next Revolution of RNA-directed Therapeutics

8 Seed $18.60M

Boston, United States

Biotechnology Health Care +1

CERo Therapeutics, Inc.

Tumor Cell Clearance Reimagined.

16 Series A $41.40M

South San Francisco, Unit...

Biotechnology Health and Wellness

BeyondSpring

Based in Duncan, South Carolina, we are a pioneering biotechnology company dedicated to ad...

51 Series A $3.75M

New York, United States

Biopharma Health Care +3

PNP Therapeutics, Inc.

Clinical-stage biopharmaceuticals developing cancer treatment platform with proprietary pr...

3 Seed $2.49M

Biotechnology Health and Wellness +1

NBE-Therapeutics AG

Next generation antibody drug conjugates

47 Series C

Basel, Switzerland

Biotechnology Health Care +1

BeiGene

BeiGene (Beijing) Co., Ltd. is a life sciences biotechnology company

2164 IPO $6.69B

Cambridge, United States

Clasp Therapeutics

Pioneering precise immuno-oncology with next-gen T cell engagers targeting specific tumor...

42 Series A $150.00M

About Adaptimmune

Designing and delivering cell therapies to transform the lives of people with cancer.

Services

Development of T-cell therapies, Pipeline management of cell therapies, Sale and licensing of cell therapies, Biotechnological research, Clinical trials

Target Customers

Cancer patients, Healthcare professionals, Biopharmaceutical companies, Medical researchers

Taxonomy

Cell Therapy, Cancer Treatment, T Cell Therapies, Preclinical Research, Clinical Development, Translational Sciences, Autologous Manufacturing, Allogeneic Manufacturing, T Cell Receptor Proteins, Affinity T Cell Receptor, Immunotherapy, Infectious Disease Treatment, HIV Therapy, Corporate Operations

Business Model

B2B, B2D

Revenue Model

Product Sales, Licensing, Service Fee

Frequently Asked Questions

Top alternatives to Adaptimmune include Imvax, Inc., Avenzo Therapeutics, Adendra Therapeutics, Enara Bio, Flare Therapeutics. These companies serve similar markets and are frequently compared.

Bounce Watch tracks 12 companies similar to Adaptimmune based on industry overlap, target customers, and business model.

Designing and delivering cell therapies to transform the lives of people with cancer.

Don't just read about them. Follow them.

BounceWatch watches Adaptimmune and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Adaptimmune Profile Imvax, Inc. Alternatives Avenzo Therapeutics Alternatives Adendra Therapeutics Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Adaptimmune on 11 Mar 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.